Cetrorelix dosing & administration
Fast-acting GnRH antagonist that stops premature ovulation during IVF cycles
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
2 documented dose levels — separate regimens, not a titration schedule
0.25 mg
Frequency
Once every 24 hours
Duration
From stimulation day 5-6 until the day of hCG (about 4-9 days)
The FDA-approved multiple-dose plan. A 0.25 mg shot under the skin each day stops an early LH surge during fertility (IVF) ovarian stimulation. [5]
3 mg
Frequency
Single dose (one injection)
Duration
One dose covers at least 4 days; add 0.25 mg daily after if hCG is delayed
Timing
Best time to take
Administer Cetrorelix at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Cetrorelix injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Cetrorelix should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting your dose
Increase if
- You've tolerated the current dose for the recommended period without significant side effects
- Therapeutic goals haven't been met at the current dose level
- Your healthcare provider recommends dose escalation based on your response
- Lab work or clinical assessments support a higher dose
Decrease if
- Side effects are bothersome or impacting daily life despite management strategies
- You experience any signs of an adverse reaction
- Lab results indicate the need for dose reduction
- Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- Therapeutic goals being met with minimal side effects
- Stable and consistent response to treatment
- Lab values or clinical markers trending in the right direction
- Good tolerance with manageable or absent side effects
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Storage
Before reconstitution
Store Cetrorelix in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
After reconstitution
Once reconstituted, Cetrorelix should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation — discard the vial
Sample daily schedule
As prescribed (once daily)
As prescribed by your healthcare provider injection
Site: Subcutaneous injection—rotate sites if applicable
Maintain a consistent schedule for optimal results with Cetrorelix. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.
Safety
Is it safe?
Side effects
Commonly reported: Injection site reactions (redness, itching, swelling), Headache, Nausea, Mild abdominal discomfort, Dizziness, Allergic reactions (rash, difficulty breathing), Ovarian hyperstimulation syndrome (OHSS) if used with other fertility drugs, Ovarian cysts, Vaginal bleeding, Mood changes, Liver enzyme changes, Pelvic pain, Severe allergic reaction
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Cetrorelix
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Cetrorelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Flagged pairings
- GnRH Agonists (Lupron, Buserelin) — Both affect GnRH signaling. Using both together would be like fighting yourself—they work against each other.
- Certain hormone contraceptives — Birth control pills taken right before cetrorelix can interfere with how well the antagonist works. Your doctor will tell you when to stop birth control.
Published research
What the studies show
Mouanness M, et al. · 2025
Cetrorelix achieves robust LH suppression comparable to newer oral GnRH antagonists in IVF cycles, with similar oocyte retrieval and fertilization rates, confirming its continued efficacy as a standard fertility treatment.
Glujovsky D, et al. · 2023
Systematic review demonstrates cetrorelix's superior performance in preventing premature LH surges during controlled ovarian hyperstimulation, with consistent clinical efficacy across diverse patient populations.
Qi Q, et al. · 2023
Cetrorelix combined with letrozole and mifepristone reduces moderate/severe OHSS from 42.3% to 20.5% in high-risk women, demonstrating its effectiveness as a key component of OHSS prevention strategies.
Tur-Kaspa I, et al. · 2009
Comprehensive review establishes cetrorelix and GnRH antagonists as superior alternatives to agonists for preventing premature ovulation, offering immediate LH suppression without the initial hormone flare.
2000
FDA-approved label: 0.25 mg administered subcutaneously once every 24 hours during the early- to mid-follicular phase, or a single 3 mg subcutaneous dose given when serum estradiol indicates an appropriate stimulation response (usually stimulation day 7, range day 5-9), with at least 4 days duration of action.
2024
Current DailyMed label confirms subcutaneous administration with the 0.25 mg daily and 3 mg single-dose regimens; if hCG is not given within 4 days of the 3 mg dose, 0.25 mg is given daily until the day of hCG.
Head to head
Cetrorelix compared
Want the full picture?
The complete Cetrorelix research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.